Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 10/20 | 0.48 |
| ▸ | JAK3 | P52333 | 8/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | INSR | P06213 | 3/20 | 0.45 |
| ▸ | LCK | P06239 | 3/20 | 0.45 |
| ▸ | LYN | P07948 | 3/20 | 0.45 |
| ▸ | HCK | P08631 | 3/20 | 0.45 |
| ▸ | SRC | P12931 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | IDH2 | P48735 | 1/20 | 0.44 |
| ▸ | CTSC | P53634 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24502 | 0.91 | SLC6A2 (0.51) | JAK2PTK2JAK3DRD2ADRA1A | |
| SCHEMBL24033 | 0.88 | EGFR (0.51) | JAK2PTK2JAK3INSRLCK | |
| SCHEMBL24602 | 0.86 | RAD52 (0.46) | JAK2PTK2JAK3KDREGFR | |
| SCHEMBL15207316 | 0.84 | KDM4E (0.44) | JAK2PTK2JAK3KDRIDH2 | |
| SCHEMBL15207975 | 0.84 | SYK (0.46) | INSRLCKLYNHCKSRC | |
| SCHEMBL24321 | 0.83 | CDK1 (0.55) | JAK2PTK2JAK3KDRIDH2 | |
| SCHEMBL24256 | 0.82 | EGFR (0.42) | JAK2PTK2JAK3SRCKDR | |
| SCHEMBL23696 | 0.80 | AURKA (0.52) | JAK2PTK2JAK3KDRIDH2 | |
| SCHEMBL24403 | 0.80 | JAK2 (0.44) | JAK2PTK2JAK3KDR | |
| SCHEMBL23085 | 0.79 | EGFR (0.53) | JAK2PTK2JAK3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | claimed |
| EP-2609098-B1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| WO-2012025186-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | SYK, IRAK1, ZAP70 | JAK2 5/4885PTK2 367/4885JAK3 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.